Yıl: 2020 Cilt: 24 Sayı: 3 Sayfa Aralığı: 192 - 200 Metin Dili: İngilizce DOI: 10.14744/AnatolJCardiol.2020.27227 İndeks Tarihi: 10-12-2020

Risk of cardiovascular events in patients with metabolic syndrome: Results of a population-based prospective cohort study (PURE Turkey)

Öz:
Objective: Metabolic syndrome (MetS) includes several cardiovascular (CV) risk factors. This study aimed to assess CV risk of MetS, contribu-tion of its components to the risk, and whether MetS provides additional risk beyond its components.Methods: The Prospective Urban Rural Epidemiology (PURE) Turkey cohort included 3933 individuals aged between 35 and 70 years, with a median follow-up of 8.9 years. MetS was diagnosed as the presence of any of the following criteria: high blood pressure, high fasting plasma glucose, abdominal obesity, low HDL-cholesterol, or high triglycerides. The primary outcome was the composite of fatal CV events, non-fatal myocardial infarction, stroke or heart failure, adjusted for age, sex, smoking, family history of CV diseases, and LDL-cholesterol.Results: The primary outcome was more common in the MetS group [178 (9.2%) vs. 70 (3.5%); corresponding incidence rate of 11.3 vs. 4.2 per 1000 person-years; log-rank p<0.001]. Each component was significantly associated with the primary outcome; however, when the components were sequentially included in the model, abdominal obesity and high triglycerides did not provide additional risk on top of the other three com-ponents. The hazard ratio for MetS for the primary outcome was 2.12 (95% confidence interval 1.59–2.81, p<0.001), and the discriminative ability (c-statistics) of the models with MetS and the components was similar.Conclusion: MetS increases the risk of CV events more than two-fold. High blood pressure, high fasting plasma glucose, and low HDL-cholester-ol are the top three components of MetS for CV risk. MetS and its components have a similar discriminative ability for CV events.(Anatol J Cardiol 2020; 24: 192-200)
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Grundy SM. Metabolic syndrome: connecting and reconciling car-diovascular and diabetes worlds. J Am Coll Cardiol 2006; 47: 1093-100.
  • 2. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and clas-sification of diabetes mellitus provisional report of a WHO consul-tation. Diabet Med 1998; 15: 539-53.
  • 3. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9: 237-52.
  • 4. Expert Panel on Detection E, Treatment of High Blood Cholester-ol in A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
  • 5. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consen-sus Group. The metabolic syndrome--a new worldwide definition. Lancet 2005; 366: 1059-62.
  • 6. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Do-nato KA, et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federa-tion Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and In-ternational Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
  • 7. Kahn R, Buse J, Ferrannini E, Stern M; American Diabetes As-sociation; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European As-sociation for the Study of Diabetes. Diabetes Care 2005; 28: 2289-304.
  • 8. Abacı A, Kılıçkap M, Göksülük H, Karaaslan D, Barçın C, Kayıkçıoğlu M, et al. Data on prevalence of metabolic syndrome in Turkey: Sys-tematic review, meta-analysis and meta-regression of epidemio-logical studies on cardiovascular risk factors. Turk Kardiyol Dern Ars 2018; 46: 591-601.
  • 9. Onat A, Ceyhan K, Basar O, Erer B, Toprak S, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels--a prospective and cross-sectional evaluation. Atherosclerosis 2002; 165: 285-92.
  • 10. Onat A, Hergenc G, Can G. Prospective validation in identical Turk-ish cohort of two metabolic syndrome definitions for predicting cardiometabolic risk and selection of most appropriate definition. Anatol J Cardiol 2007; 7: 29-34.
  • 11. Kozan O, Oguz A, Abaci A, Erol C, Ongen Z, Temizhan A, et al. Preva-lence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr 2007; 61: 548-53.
  • 12. Mente A, Yusuf S, Islam S, McQueen MJ, Tanomsup S, Onen CL, et al. Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries. J Am Coll Cardiol 2010; 55: 2390-8.
  • 13. Simons LA, Simons J, Friedlander Y, McCallum J. Is prediction of cardiovascular disease and all-cause mortality genuinely driven by the metabolic syndrome, and independently from its component variables? The Dubbo study. Heart Lung Circ 2011; 20: 214-9.
  • 14. Mayer O Jr., Bruthans J, Seidlerova J, Karnosova P, Vanek J, Hron-ova M, et al. Prospective study of metabolic syndrome as a mortal-ity marker in chronic coronary heart disease patients. Eur J Intern Med 2018; 47: 55-61.
  • 15. Church TS, Thompson AM, Katzmarzyk PT, Sui X, Johannsen N, Ear-nest CP, et al. Metabolic syndrome and diabetes, alone and in com-bination, as predictors of cardiovascular disease mortality among men. Diabetes Care 2009; 32: 1289-94.
  • 16. Lyubarova R, Robinson JG, Miller M, Simmons DL, Xu P, Abramson BL, et al.; Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) Investigators. Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial. J Clin Lipidol 2017; 11: 1201-11.
  • 17. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414-9.
  • 18. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP; San An-tonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110: 1251-7.
  • 19. Alexander CM, Landsman PB, Teutsch SM, Haffner SM; Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210-4.
  • 20. Younis A, Goldkorn R, Goldenberg I, Geva D, Tzur B, Mazu A, et al. Impaired Fasting Glucose Is the Major Determinant of the 20-Year Mortality Risk Associated With Metabolic Syndrome in Nondiabet-ic Patients With Stable Coronary Artery Disease. J Am Heart Assoc 2017; 6: e006609.
  • 21. Teo K, Chow CK, Vaz M, Rangarajan S, Yusuf S; PURE Investigators-Writing Group. The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic non-communicable diseases in low-, middle-, and high-income coun-tries. Am Heart J 2009; 158: 1-7.
  • 22. Oğuz A, Telci Çaklılı Ö, Tümerdem Çalık B; PURE Investigators. The Prospective Urban Rural Epidemiology (PURE) study: PURE Turkey. Turk Kardiyol Dern Ars 2018; 46: 613-23.
  • 23. Gunes FE, Imeryuz N, Akalin A, Bekiroglu N, Alphan E, Oguz A, et al. Development and validation of a semi-quantitative food frequency questionnaire to assess dietary intake in Turkish adults. J Pak Med Assoc 2015; 65: 756-63.
  • 24. Ural D, Kılıçkap M, Göksülük H, Karaaslan D, Kayıkçıoğlu M, Özer N, et al. Data on prevalence of obesity and waist circumference in Turkey: Systematic review, meta-analysis and meta regression of epidemiological studies on cardiovascular risk factors. Turk Kardi-yol Dern Ars 2018; 46: 577-90.
  • 25. Udell JA, Steg PG, Scirica BM, Eagle KA, Ohman EM, Goto S, et al.; Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metabolic syndrome, diabetes mellitus, or both and cardiovascular risk in outpatients with or at risk for ath-erothrombosis. Eur J Prev Cardiol 2014; 21: 1531-40.
  • 26. Oğuz A, Temizhan A, Abaci A, Kozan O, Erol C, Ongen Z, et al. Obe-sity and abdominal obesity; an alarming challenge for cardio-meta-bolic risk in Turkish adults. Anatol J Cardiol 2008; 8: 401-6.
APA Oguz A, KESKİNER M, KILIÇKAPI M, GÜLEÇ H, ALTUNTAŞ Y, Karşıdağ K, Temizhan A, ÇALIK B, RANGARAJAN S, YUSUF S (2020). Risk of cardiovascular events in patients with metabolic syndrome: Results of a population-based prospective cohort study (PURE Turkey). , 192 - 200. 10.14744/AnatolJCardiol.2020.27227
Chicago Oguz Aytekin,KESKİNER Miraç Vural,KILIÇKAPI Mustafa,GÜLEÇ H. Sadi,ALTUNTAŞ Yüksel,Karşıdağ Kubilay,Temizhan Ahmet,ÇALIK Burcu Tümerdem,RANGARAJAN Sumathy,YUSUF Salim Risk of cardiovascular events in patients with metabolic syndrome: Results of a population-based prospective cohort study (PURE Turkey). (2020): 192 - 200. 10.14744/AnatolJCardiol.2020.27227
MLA Oguz Aytekin,KESKİNER Miraç Vural,KILIÇKAPI Mustafa,GÜLEÇ H. Sadi,ALTUNTAŞ Yüksel,Karşıdağ Kubilay,Temizhan Ahmet,ÇALIK Burcu Tümerdem,RANGARAJAN Sumathy,YUSUF Salim Risk of cardiovascular events in patients with metabolic syndrome: Results of a population-based prospective cohort study (PURE Turkey). , 2020, ss.192 - 200. 10.14744/AnatolJCardiol.2020.27227
AMA Oguz A,KESKİNER M,KILIÇKAPI M,GÜLEÇ H,ALTUNTAŞ Y,Karşıdağ K,Temizhan A,ÇALIK B,RANGARAJAN S,YUSUF S Risk of cardiovascular events in patients with metabolic syndrome: Results of a population-based prospective cohort study (PURE Turkey). . 2020; 192 - 200. 10.14744/AnatolJCardiol.2020.27227
Vancouver Oguz A,KESKİNER M,KILIÇKAPI M,GÜLEÇ H,ALTUNTAŞ Y,Karşıdağ K,Temizhan A,ÇALIK B,RANGARAJAN S,YUSUF S Risk of cardiovascular events in patients with metabolic syndrome: Results of a population-based prospective cohort study (PURE Turkey). . 2020; 192 - 200. 10.14744/AnatolJCardiol.2020.27227
IEEE Oguz A,KESKİNER M,KILIÇKAPI M,GÜLEÇ H,ALTUNTAŞ Y,Karşıdağ K,Temizhan A,ÇALIK B,RANGARAJAN S,YUSUF S "Risk of cardiovascular events in patients with metabolic syndrome: Results of a population-based prospective cohort study (PURE Turkey)." , ss.192 - 200, 2020. 10.14744/AnatolJCardiol.2020.27227
ISNAD Oguz, Aytekin vd. "Risk of cardiovascular events in patients with metabolic syndrome: Results of a population-based prospective cohort study (PURE Turkey)". (2020), 192-200. https://doi.org/10.14744/AnatolJCardiol.2020.27227
APA Oguz A, KESKİNER M, KILIÇKAPI M, GÜLEÇ H, ALTUNTAŞ Y, Karşıdağ K, Temizhan A, ÇALIK B, RANGARAJAN S, YUSUF S (2020). Risk of cardiovascular events in patients with metabolic syndrome: Results of a population-based prospective cohort study (PURE Turkey). The Anatolian Journal of Cardiology, 24(3), 192 - 200. 10.14744/AnatolJCardiol.2020.27227
Chicago Oguz Aytekin,KESKİNER Miraç Vural,KILIÇKAPI Mustafa,GÜLEÇ H. Sadi,ALTUNTAŞ Yüksel,Karşıdağ Kubilay,Temizhan Ahmet,ÇALIK Burcu Tümerdem,RANGARAJAN Sumathy,YUSUF Salim Risk of cardiovascular events in patients with metabolic syndrome: Results of a population-based prospective cohort study (PURE Turkey). The Anatolian Journal of Cardiology 24, no.3 (2020): 192 - 200. 10.14744/AnatolJCardiol.2020.27227
MLA Oguz Aytekin,KESKİNER Miraç Vural,KILIÇKAPI Mustafa,GÜLEÇ H. Sadi,ALTUNTAŞ Yüksel,Karşıdağ Kubilay,Temizhan Ahmet,ÇALIK Burcu Tümerdem,RANGARAJAN Sumathy,YUSUF Salim Risk of cardiovascular events in patients with metabolic syndrome: Results of a population-based prospective cohort study (PURE Turkey). The Anatolian Journal of Cardiology, vol.24, no.3, 2020, ss.192 - 200. 10.14744/AnatolJCardiol.2020.27227
AMA Oguz A,KESKİNER M,KILIÇKAPI M,GÜLEÇ H,ALTUNTAŞ Y,Karşıdağ K,Temizhan A,ÇALIK B,RANGARAJAN S,YUSUF S Risk of cardiovascular events in patients with metabolic syndrome: Results of a population-based prospective cohort study (PURE Turkey). The Anatolian Journal of Cardiology. 2020; 24(3): 192 - 200. 10.14744/AnatolJCardiol.2020.27227
Vancouver Oguz A,KESKİNER M,KILIÇKAPI M,GÜLEÇ H,ALTUNTAŞ Y,Karşıdağ K,Temizhan A,ÇALIK B,RANGARAJAN S,YUSUF S Risk of cardiovascular events in patients with metabolic syndrome: Results of a population-based prospective cohort study (PURE Turkey). The Anatolian Journal of Cardiology. 2020; 24(3): 192 - 200. 10.14744/AnatolJCardiol.2020.27227
IEEE Oguz A,KESKİNER M,KILIÇKAPI M,GÜLEÇ H,ALTUNTAŞ Y,Karşıdağ K,Temizhan A,ÇALIK B,RANGARAJAN S,YUSUF S "Risk of cardiovascular events in patients with metabolic syndrome: Results of a population-based prospective cohort study (PURE Turkey)." The Anatolian Journal of Cardiology, 24, ss.192 - 200, 2020. 10.14744/AnatolJCardiol.2020.27227
ISNAD Oguz, Aytekin vd. "Risk of cardiovascular events in patients with metabolic syndrome: Results of a population-based prospective cohort study (PURE Turkey)". The Anatolian Journal of Cardiology 24/3 (2020), 192-200. https://doi.org/10.14744/AnatolJCardiol.2020.27227